Riskpilot← Back to searchSign inGet full accessNovoSense AB
ABActiveOrg 5566643192LundManufacture of medical and dental instruments and supplies · NACE 3250Est. 20042 employees
Revenue 2024
SEK 0
EBITDA margin
—
-3% vs 2023
Equity ratio
95.0%
Financial strength
Net profit 2024
SEK -5M
0% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -3,5M | -3% |
| Net profit | SEK -5M | +0% |
| Total assets | SEK 22,5M | +42% |
| Equity | SEK 21,4M | +45% |
| Employees | 2 | — |
Legal name
NovoSense AB
Org number
5566643192
Legal form
Aktiebolag
NACE code
3250 · Manufacture of medical and dental instruments and supplies
Founded
23 juli 2004
Share capital
SEK 465 800
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall utveckla patientmonitoreringsutrustning ävensom idka därmed förenlig verksamhet.
Address
Lund
Phone
+46733538880
Email
jonas.tilly@novosense.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | −1 781 |
| EBITDA | −7 | −1 191 | −1 501 | −3 447 | −3 546 |
| Depreciation & amort. | −1 487 | −1 088 | −1 716 | −1 652 | −1 641 |
| EBIT | −1 494 | −2 279 | −3 217 | −5 099 | −5 187 |
| Net financials | −1 | −3 | — | 91 | 161 |
| Profit before tax | −1 495 | −2 281 | −3 218 | −5 009 | −5 026 |
| Tax | −0 | −0 | −0 | −0 | — |
| Net profit | −1 495 | −2 281 | −3 218 | −5 009 | −5 026 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 7 607 | 13 290 | 9 366 | 15 840 | 22 542 |
| Equity | 6 241 | 11 451 | 8 233 | 14 791 | 21 411 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 1 366 | 1 839 | 1 133 | 1 048 | 1 131 |
| Total debt | 1 366 | 1 839 | 1 133 | 1 048 | 1 131 |
EBITDA margin
-354568400.0%
This company
15.8%
Market median
-2244103897% vs market
20202024
Equity ratio
95.0%
This company
38.2%
Market median
+149% vs market
20202024
Return on equity
-23.5%
This company
18.4%
Market median
-228% vs market
20202024
Net profit margin
-502581700.0%
This company
8.1%
Market median
-6204712446% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HO | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Former (1) | ||
| Board of Directors | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NovoSense AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Henry Oskar Stefan Svensson | Audit | 0 companies |
| Lars Johan Christopher Fägerskiöld | Board of Directors | 0 companies |
| Maria Inger Christina Tilly | Deputy Board Member | 0 companies |
| Carl Fredrik Paul Sebelius | Board of Directors | 0 companies |
| Solveig Maria Bergström | Board of Directors | 0 companies |
| Lars Kenneth Jonas Tilly | Chairman | 0 companies |